Ainos, Inc. reported significant financial developments in its 2025 fiscal year, with revenues reaching $124,157, a substantial increase from $20,729 in 2024, marking a 499% rise. The revenue growth was primarily driven by the commercialization of its AI Nose platform, which generated $123,360 in revenue, while pet supplements contributed $797. The company also reported a gross profit of $102,911, a notable recovery from a gross loss of $31,866 in the previous year. Despite this positive revenue trajectory, Ainos continued to face operating losses, reporting a net loss of $14,771,012, slightly down from $14,863,161 in 2024.
In terms of operational changes, Ainos made strides in advancing its AI Nose platform towards early commercialization, particularly in industrial applications such as semiconductor manufacturing and robotics. The company secured a commercial order valued at approximately $2.1 million for the deployment of 1,400 AI Nose systems, alongside a minimum order commitment for an additional 600 units. These developments are part of Ainos's strategy to expand its industrial ecosystem and validate its technology in real-world settings, which is expected to enhance its market position.
The company also continued to develop its VELDONA® therapeutic programs, focusing on rare and autoimmune diseases. Clinical studies for indications such as oral warts in HIV-positive patients and Sjögren’s syndrome are ongoing in Taiwan, with expectations for key milestones in 2026-2027. Ainos has emphasized a selective and capital-efficient approach to managing its healthcare-related programs, which may influence future revenue streams.
As of December 31, 2025, Ainos had cash and cash equivalents of $417,353, a decrease from $3,892,919 in 2024. The company reported net cash used in operating activities of $4,614,697, a reduction from $5,808,267 in the previous year, indicating improved cash flow management. However, Ainos acknowledged the need for additional financing to support its operations and product development, highlighting the uncertainty surrounding its ability to achieve profitability in the near term.
Looking ahead, Ainos plans to focus on scaling its AI Nose platform and advancing its VELDONA® programs while managing investments prudently. The company aims to leverage its partnerships and increase the volume of scent data generated to refine its technology further. However, Ainos also cautioned that its future performance may be influenced by market conditions, regulatory approvals, and the pace of adoption of its technologies.
About Ainos, Inc.
Ainos, Inc. is a diversified healthcare company specializing in novel point-of-care testing (POCT), low-dose interferon alpha therapeutics (VELDONA), and synthetic RNA-based preventative medicine. Its product portfolio includes VELDONA Pet supplements and AI-powered VOC sensing POCT devices for rapid, non-invasive health diagnostics. Operating primarily in Taiwan, Ainos leverages outsourced manufacturing and global distribution partnerships to develop affordable, telehealth-friendly healthcare solutions targeting human and animal health markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.